Unmet Needs and Future Treatments of Idiopathic Pulmonary Fibrosis : Episode 7

Opinion

Video

August 1, 2024

Therapeutic Response and Disease Progression

Author(s):

Justin Oldham, MD, MS

An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.

EP: 1.Emerging Agents in IPF Treatment

EP: 2.IPF and PDE4B Inhibitors

EP: 3.Importance of Patient-Reported Outcomes

EP: 4.Future Possibilities in IPF Treatment

EP: 5.Advice for Clinicians Treating IPF

EP: 6.Current Standard of Care in IPF

EP: 7.Therapeutic Response and Disease Progression

EP: 8.Key Considerations for Selecting IPF Treatment

EP: 9.Economic Impact of IPF

EP: 10.Unmet Needs in IPF Landscape

EP: 11.Overview of Idiopathic Pulmonary Fibrosis (IPF)

EP: 12.Impact of IPF on Quality of Life and Financial Considerations

EP: 13.Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection

EP: 14.Clinical Presentation and Risk Factors

EP: 15.Impact of Comorbidities on IPF Management

EP: 16.Overcoming Treatment Barriers: Strategies for Success

EP: 17.Impact of Treatment Delays on Patient Outcomes

Video content above is prompted by the following:

How can multidisciplinary care be optimized when treating patients with IPF?
Describe the therapeutic response and disease progression of patients taking standard of care therapies (pharmacologic and non-pharmacologic).

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

1 expert in this video

Ayodeji Adegunsoye, MD, PhD, MSc

4 experts in this video

4 experts in this video

Marilyn Glassberg, MD

Dr Caroline Vovan

Related Content

Woman and child holding red ribbon | Image credit: ArvStd - stock.adobe.com

July 24th 2025

High Burdens of Drug Resistance Found in Children With HIV

Julia Bonavitacola

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with HIV.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

The findings showed that certain IPF phenotypes had a significant association with hypothyroidism. | Image credit: surasak - stock.adobe.com

July 23rd 2025

Immune Cell Phenotypes Linked With Hypothyroidism, IPF

Jared Kaltwasser

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Adcetris packaging | Image: Pfizer

July 23rd 2025

Real-World Study Finds Brentuximab Vedotin With Chemo Is Safe, Effective in First-line Treatment of PTCL

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient outcomes and cancer care globally.

Related Content

Woman and child holding red ribbon | Image credit: ArvStd - stock.adobe.com

July 24th 2025

High Burdens of Drug Resistance Found in Children With HIV

Julia Bonavitacola

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with HIV.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

The findings showed that certain IPF phenotypes had a significant association with hypothyroidism. | Image credit: surasak - stock.adobe.com

July 23rd 2025

Immune Cell Phenotypes Linked With Hypothyroidism, IPF

Jared Kaltwasser

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Adcetris packaging | Image: Pfizer

July 23rd 2025

Real-World Study Finds Brentuximab Vedotin With Chemo Is Safe, Effective in First-line Treatment of PTCL

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient outcomes and cancer care globally.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions